Nuvation Bio (NUVB) Citigroup’s Biopharma Back to School Summit 2026 summary

Product performance and market position

• IBTROZI achieved FDA approval over a year ago and has become the leading ROS1 TKI, with strong launch performance and unmatched duration and response rates exceeding four years.

• IBTROZI faces minimal competition due to superior efficacy and safety profile, with no CNS warnings or significant adverse events compared to competitors.

• Safusidenib demonstrated unprecedented three-year data in glioma, with a 52% response rate and 79% non-progression rate, outperforming existing therapies.

• Multiple pivotal studies for safusidenib are enrolling, with robust cash reserves of about $700 million supporting ongoing development and profitability.

• Internal DDC platform programs are progressing, with updates expected later in the year.

Market dynamics and growth strategies

• 85% of IBTROZI patients are first-line, but increased adoption is challenged by persistent IO chemo use despite NCCN guidelines contraindicating IO for ROS1 disease.

• Educational efforts at community centers have doubled or tripled ROS1 TKI use, highlighting the impact of targeted outreach.

• Testing rates for ROS1 remain suboptimal in community settings, with ongoing efforts to improve biomarker testing and guideline adoption.

• Advances in NGS automation and broader biomarker testing are expected to drive further uptake of precision oncology agents.

• Outside the U.S., partnerships (e.g., with Eisai in Europe) and high testing rates in Asia support global expansion, with fewer challenges from IO chemo.

Market opportunity and financial outlook

• U.S. market for IBTROZI estimated at $1 billion annually, potentially exceeding $4 billion by year four due to long duration of therapy; RNA testing could further expand TAM to $5+ billion.

• Real-world data show IBTROZI’s duration of therapy aligns with clinical trials, with low discontinuation rates and strong tolerability.

• Safusidenib’s market could dwarf IBTROZI’s, as low-grade glioma patients have much longer durations of response and higher pricing potential.

• Vorasidenib’s rapid commercial uptake validates the glioma market size, with safusidenib positioned to capture patients progressing on vorasidenib.

• Positive KOL feedback and robust trial enrollment support safusidenib’s perceived superiority and market potential.